Thromb Haemost 1973; 29(03): 633-643
DOI: 10.1055/s-0038-1648105
Original Article
Schattauer GmbH

Cold Promoted Activation of Factor VII VI. Effect of Inhibitors

H Gjønnæss
1   Institute for Thrombosis Research, University of Oslo, Rikshospitalet, Oslo (Chief: H. Stormorken)
› Author Affiliations
Further Information

Publication History

Publication Date:
30 June 2018 (online)

Summary

The cold promoted activation of factor VII occurs in parallel with an activation of a plasma arginine esterase, and, on inhibition of the cold activation of factor VII, the esterase activation also decreased. The inhibitor pattern supported our theory that the arginine esterase that is activated in the cold activation of factor VII is plasma kallikrein.

The cold activation of factor VII was completely inhibited with soya bean trypsin inhibitor in doses that did not interfere with the contact activation. On the other hand, inhibition of the contact activation with hexadimethrine bromide did not interfere with the cold activation of factor VII except when this was kaolin induced. Contact and cold activation therefore appear to represent two different pathways for the activation of factor VII. The cold activation reaction is probably mediated by the activation of plasma prekallikrein, and inhibition of the plasma kallikrein activity correlates with the inhibition of the cold promoted activation of factor VII.

 
  • References

  • 1 Alkjaersig N, Fletcher A. P, Sherry S. 1959; The mechanism of clot dissolution by plasmin. Journal of Clinical Investigation 38: 1086.
  • 2 Altman R, Hemker H. C. 1967; Contact activation in the extrinsic blood clotting system. Thrombosis et Diathesis Haemorrhagica 18: 525.
  • 3 Amris C. J, Hilden M. 1967; Inhibition of thromboplastic activity by Trasylol®. Scandinavian Journal of Haematology, 4 : 3.
  • 4 Armstrong D. 1969. Hageman factor and the spontaneous human plasma kinin generation occurring in homogenous media. Activation and inactivation. In: Inflammation Biochemistry and Drug Interaction. Exerpta Medica Foundation: Amsterdam; 153.
  • 5 Back N, Steg-er H. 1968; Effect of inhibitors on kinin-releasing activity of proteases. Federation Proceedings 27: 96.
  • 6 Blombäck B, Blombäck M, Olsson P. 1967; Action of a proteolytic enzyme inhibitor on blood coagulation in vitro. Thrombosis et Diathesis Haemorrhagica 18: 190.
  • 7 Brozoviö M, Gurd L. J. 1971. Activation of factor VII. Abstr. vol. Und Congress, The International Society on Thrombosis and Haemostasis. Oslo; July 1971, 6.
  • 8 Claeys H, Amery A, Verhaeghe R. 1971; Proteolytic activity of the activator produced by streptokinase in human plasma. Thrombosis et Diathesis Haemorrhagica 26: 88.
  • 9 Colman R. W, Mattler L. Sherry 1969; Studies on the prekallikrein (kallikreinogen) - kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. Journal of Clinical Investigation 48: 23.
  • 10 Donaldson V. H. 1968; C’l activation in hereditary angioneurotic edema plasma: role of urokinase and inhibitors. Journal of Applied Physiology 25: 416.
  • 11 Egeberg O. 1961; Assay of antihemophilic A, B and C factors by one-stage cephalin systems. Scandinavian Journal of Clinical and Laboratory Investigation 13: 140.
  • 12 Eisen V. 1963; Observation on intrinsic kinin-forming factors in human plasma: the effect of acid, acetone, chloroform, heat and euglobulin separation on kinin formation. Journal of Physiology 166: 496.
  • 13 Eisen V. 1964; Effect of hexadimethrine bromide on plasma kinin formation, hydrolysis of p-tosyl-l-arginine methyl ester and fibrinolysis. British Journal of Pharmacology 22: 87.
  • 14 Eisen V, Glanville K. L. A, Collins A. J, Smith H. G.-. 1970; Observations on plasma kinin forming enzymes. Advances in experimental Medicine and Biology 08: 11.
  • 15 Feeney R. E, Means G. E, Bigler J. C. 1969; Inhibition of human trypsin, plasmin, and thrombin by naturally occurring inhibitors of proteolytic enzymes. The Journal of Biological Chemistry 244: 1957.
  • 16 Gjonnæss H. 1972a Cold promoted activation of factor VII. I. Evidence for the existence of an activator. Thrombosis et Diathesis Haemorrhagica 28: 155.
  • 17 Gjonnæss H. 1972b Cold promoted activation of factor VII. II. Identification of the activator. Thrombosis et Diathesis Haemorrhagica 28: 169.
  • 18 Gjonnæss H. (1972 c) Cold promoted activation of factor VII. III. Relation to the kallikrein system. Thrombosis et Diathesis Haemorrhagica 28: 182.
  • 19 Gjonnæss H. 1972d Cold promoted activation of factor VII. IV. Relation to the coagulation system. Thrombosis et Diathesis Haemorrhagica 28: 194.
  • 20 Gjonnæss H. 1973; Cold promoted activation of factor VII. V. Relation to the fibrinolytic system. Thrombosis et Diathesis Haemorrhagica 29: 143.
  • 21 Gjonnæss H, Laake K. 1973 Activation of human factor VII in crude preparations with plasma kallikrein activity. Acta Pharmacologica et Toxicologica, to be published..
  • 22 Hemker H. C, Siepel T, Altman R, Loeliger E. A. 1967; Kinetic aspects of the interaction of blood-clotting enzymes. II. The relation between clotting time and plasma concentration in prothrombin-time estimations. Thrombosis et Diathesis Haemorrhagica 27: 349.
  • 23 Johnston C. L, Hjort P. F. 1961; Development of increased factor VII activity during the spontaneous coagulation of blood. Journal of Clinical Investigation 40: 743.
  • 24 Josso F, Béguin S. 1969. The possible role of factor VII in the intrinsic system. In: Hemker H. C, Loeliger E. A, Veltkamp J. J. (eds.) Boerhaave Series: Human Blood Coagulation. Leiden University Press; Leiden: 77.
  • 25 Laake K, Gjonnæss H, Fagerhol M. K. 1973 Components of the kallikrein-kinin system and the spontaneous activation of factor VII in human plasma. Acta Pharmacologica et Toxicologica, to be published..
  • 26 McDonagh R. P, Ferguson J. H. 1970; Studies on the participation of Hageman factor in fibrinolysis. Thrombosis et Diathesis Haemorrhagica 24: 1.
  • 27 Nossel H. L, Niemetz J. 1965; A normal inhibitor of the blood coagulation contact reaction product. Blood 25: 712.
  • 28 Nossel H. L, Rubin H, Drillings M, Hsieh R. 1968; Inhibition of Hageman factor activation. The Journal of Clinical Investigation 47: 1172.
  • 29 Owren P. A. 1959; Thrombotest. A new method for controlling anticoagulant therapy. Lancet 02: 754.
  • 30 Prentice C. R. M, McNicol G. P, Douglas A. S. 1970; Studies on the anticoagulant action of Aprotinin (“Trasylol”). Thrombosis et Diathesis Haemorrhagica 24: 265.
  • 31 Ratnoff O. D. 1966. The biology and pathology of the initial stages of blood coagulation. In Brown E. B, Moore C. V. (eds.) Progress in Hematology. Grune & Stratton; New York and London: 204.
  • 32 Ratnoff O. D, Lepow I. H. 1957; Some properties of an esterase derived from preparations of the first component of complement. Journal of Experimental Medicine 106: 327.
  • 33 Robbins K. C, Summaria L. 1966; An immunochemical study of human plasminogen and plasmin. Immunochemistry 03: 29.
  • 34 Soulier J-P, Protj-Wartelle O. 1960; New data on Hageman factor and plasma thromboplastin antecedent : The role of “contact” in the initial phase of blood coagulation. British Journal of Haematology 06: 88.
  • 35 SuGriHARA H, Nagasawa S, Suzuki T. 1971; Studies on 03B1;2-macroglobulin in bovine plasma. III. Its actions on bovine plasma kallikrein, plasmin and thrombin. Journal of Biochemistry 70: 649.
  • 36 Vogt W, Wawretschek W. 1968; Weitere U nt er suchungen zur Existenz zweier kininbildender Systeme in menschlichem Plasma. Naunym Schmiedebergs Archiv für Pharmakologie und exp er iment eile Pathologie 260: 223.
  • 37 Waaler B. A. 1959. Contact Activation in the Intrinsic Blood Clotting System. Thesis. Oslo University Press; Oslo.:
  • 38 Webster M. E, Pierce J. V. 1961; Action of the kallikreins on synthetic ester substrates. Proceedings of the Society for Experimental Biology and Medicine 107: 186.
  • 39 Wuepper K. D, Cochrane C. G. 1972; Plasma prekallikrein : Isolation, characterization, and mechanism of activation. The Journal of Experimental Medicine 135: 1.